Pricing
  1. JP-listed companies
  2. ADR120S, Inc.
  3. Financials
  4. EBITDA margin (%)

ADR120S, Inc.【JP:3750】

Market cap
¥7.9B
P/E ratio
110.7x
Saitori Cell Research Institute develops regenerative cell therapies and medical devices while also investing in real estate projects through seven subsidiaries.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA margin (%) YoY (%)
Mar 31, 2025-619.7+1613.42%
Mar 31, 2024-36.2+52.46%
Mar 31, 2023-23.7+69.25%
Mar 31, 2022-14-58.57%
Mar 31, 2021-33.8-2027.94%
Mar 31, 20201.8-90.16%
Mar 31, 201917.8-33.47%
Mar 31, 201826.8-285.13%
Mar 31, 2017-14.5+69.60%
Mar 31, 2016-8.5-173.53%
Mar 31, 201511.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)